I've met so many entrepreneurial rare disease parents over the years that I’ve lost count.
They have moved or are moving medical mountains to save their kids and others like them.
But rare parent founders get no love from institutional players.
Those days are done.
Science, talent and compute are no longer limiting.
Priority Review Voucher alpha makes the economics work.
The missing spark is access to cure capital.
That's why I’m incredibly pumped to relaunch @1000cures with my cofounder @ryan_1000cures!
Ryan and I teamed up to create a “YC for Rare” that unites our biotech houses with complementary expertises, experiences and networks.
1000 Cures is an accelerator for lean startups led by parents on mission to cure pediatric rare diseases.
We ride at dawn.
Let’s go!
We @Dyno_Tx (+ our partners) can do that with 2% of that budget, probably faster than them if they set out to do it tomorrow.
Not to say I'm not excited for what they will do with this allocation. Their work is pioneering and inspiring.
But curing 1000s of monogenic disease is likely too hard for them in the next few years:) It's not just an AI problem. Requires very high integration between AI and lab/clinic to make the AI count.
Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once...
I received a lot of DMs and comments on this tweet. To be clear, AI doesn't guarantee drug approval or replace wet-lab validation and clinical trials. It's a force multiplier on the 2 biggest constraints: (1) low probability of success (~90% of drugs fail and ~10 of patients achieve remission of chronic disease), and (2) slow, manual operational processes. The question isn't "Will AI magically invent a cure tomorrow?" but "Given the current inefficiencies, can we afford not to use systems that could raise the quality and speed of attempts?" If you combine the intelligence of the smartest people who ever lived with everything humanity has written and the ability to run millions of simulations, it would be odd, with full-throated confidence, to claim that AI could not help find better drugs. The data so far says it already is.
The Biotocracy is up in arms about the “cure all diseases in 10 years” comment.
Future cure ≠ FDA Approval (2026)
Will the regulatory pathways and timelines look different in 2031, 2036? YES
Could there be a scientific breakthrough tomorrow, that the scientific consensus could not conceive of yesterday? YES
Just look at the recent DREADDs data for epilepsy that stunned.
e/acc
NEW: An AI researcher at Anthropic runs a business that hosts "consensual non-consent" orgies in the Bay Area. The orgies have been the subject of sexual assault allegations and sparked debate about the AI industry's attitudes toward women, some of whom report feeling pressured to attend the orgies in order to advance their careers.
Paul Crowley, a cybersecurity researcher at Anthropic, is listed as a manager of Red Means No LLC, which says that its parties are "designed to be spaces to … ignore the 'nos' of others." Participants can use a safe word, "red," to end an encounter but give "default consent" to "spanking," "wrestling," and "light pain" by entering the orgy, according to Red Means No's website. More extreme actions, including "light electricity" and "moderate beatings," are "permitted with negotiation," though "body-shaming and race-shaming … are disallowed entirely."
The orgies have been known to attract a disproportionate number of employees at Anthropic and OpenAI, a dynamic critics say creates professional pressure for women in AI to attend. The criticism spilled into public view last month after an independent AI researcher, John Wentworth, said that he "absolutely [does] upgrade" his assessment of AI safety experts "if I find out they go to [Red Means No]," adding that attendance was a "strong signal" of free thought.
"Want to get ahead in your AI career? Go to the rape orgy," Substacker Ivy Asterix quipped. At least one woman claims to have been sexually assaulted at Red Means No, which the group describes as a "safe space" to have "your resistance ignored."🧵
freebeacon.com/america/horri…
things that are theoretically possible in biotech that too few people are working on:
> new interfaces for neuromodulation
> joint biological and physical autonomous surgeries
> mining drugs from parasites and poisonous creatures
> cancer, alzheimer's, anemia prevention drugs /vaccines
> mosquito sequencing for biosurveillance
> mapping how the exposome influences disease > in vivo detox medicines
> AI -enabled wearables, ingestibles, implantables
> next-generation organ replacments
> LVMH for bio
> new endometriosis and menopausal medicines
> biotech for endangered species
> nanomedicines
> personalized tissue aging platform
> consumer immunome/proteome/metabolome diagnostics
> self-amplifying drugs
> ozempic for muscles, sleep, pain, cognition, hair, tanning
more in the link below -
All @JensenHuang has to do is tweet that he wants to be reinstated as CEO and gears will start moving.
If Jensen says he wants back in, all of Nvidia and indeed the global AI ecosystem is still wired around him. The coup has no legitimacy. The anti-Jensen board members will immediately step down or likely be legally forced out.
Under Nvidia’s bylaws, shareholders with at least 15% of votes for one year can demand a special meeting to remove sitting directors (requiring a simple majority with cause, or a 2/3 supermajority without) and elect a new board.
And anti-Jensen board members know they’ll be held responsible for $1T in market cap erased if they hold out against the Jensen restoration. But these are NPCs, so they’ll buckle quickly.
Trump also realizes there’s no way that removing his top AI CEO, namely Jensen Huang, will somehow keep him on top in AI (sorry, SI). He can overrule any lieutenant who pushed too far in their attempt to do to Jensen Huang what Xi did to Jack Ma. This “spy” nonsense is just like Russiagate, the exact kind of fake story that Trump himself was subject to, so he gets it.
After all, there’s really only a tiny minority of evil conspirators in media and politics who actually wanted Jensen Huang out of the company he built from scratch. Almost everyone else in tech, both inside and outside Nvidia, from billion dollar funds to unicorn founders, admires and respects one of the greatest CEOs of all time.
Jensen just has to ask for his company back. And an army will rally behind him.
It’s understandable why so many companies chase the same drug targets. Once the biology is validated, the risk can be lower and the odds of success better. Competition can also produce better medicines.
But if we all follow the same trail, who takes on the diseases where the biology is still uncharted?
As I said in my last post, AI could help make more diseases worth pursuing. The real opportunity is to use it to better understand disease, identify novel targets and take intelligent risks on unmet needs. That’s how we get beyond more drugs for the same targets and bring new hope to more patients.
Why does every AI Bio company sounds exactly like Theranos?
"a CRO but really fast" (with no tech innovation, no experience in biology) sounds a lot like "a blood test but from a really small amount"
Unfortunately, there is an enormous gap in biological data. While the impact of AI will be incredible, it will sadly be a very long time before disease is a “relic of the past.”
Why are old stories that were not even covered up all that well become sudden international and geopolitical news?
The timing is suspicious, so worth asking: who benefits and why now?
If Jensen, the premier champion of open models, is taken out then anyone who wants AI closed, centralized, and controlled might benefit.
Why now? The midterms seem relevant. But also perhaps the upcoming IPOs.
Breaking: Nvidia’s board is preparing to oust CEO Jensen Huang after he had two extramarital affairs, including one with a suspected Chinese spy. on.wsj.com/4jcpr01